SOURCE: Xtalks

Xtalks Webinars

June 21, 2016 07:00 ET

First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines, Quotient Clinical Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - June 21, 2016) - On Tuesday, July 12, 2016, industry experts Dr Alyson Connor, Executive Director of Exploratory Clinical Pharmacology at Quotient Clinical, and Dr Ofir Moreno, the Vice President of R&D at MEI Pharma, Inc., will outline how Enabled-First-in-Human® programs integrate real-time GMP drug product manufacturing with healthy volunteer and patient clinical testing into a seamless early development plan. The effect is to significantly reduce time to proof-of-concept, minimize up-front investment and simplify supply chains.

Increasing pressure on R&D budgets means the design, speed and precision of early phase clinical programs is critical for success. The traditional staged approach to drug development has involved discrete clinical studies in Phase I and Phase II, separated by decision steps. However, increasingly protocols are being combined or interleaved to accelerate the pathway to POC.

In addition to optimizing the clinical plan, pharmaceutical project teams now also demand more data than ever before to answer key "developability" questions in Phase I. Can we assess the impact of formulation and formulation performance? How can one rapidly manufacture GMP product for Phase I? What drug product will one use for Phase II? Is there a valid biomarker to establish an early pharmacodynamics response? Are there any metabolism or bioavailability issues that need to be addressed?

This webinar will present a set of case studies on:

  • Integrated single and multiple ascending dose studies combining healthy volunteer and POC investigations
  • Real-time adaptive GMP manufacturing to enable dose, formulation and product changes within a clinical protocol in response to emerging clinical data
  • Continuous supply of clinical trial material (CTM) to global clinical sites post-Phase I, avoiding the need for tech transfer and scale up prior to Phase II

Dr Ofir Moreno from MEI Pharma, Inc will present the design and results of an early development program of a new molecule ME-401, which is in development for the treatment of lymphoid malignancies. Dr Alyson Connor from Quotient Clinical will present further cases studies illustrating the applications and benefits of Enabled-FIH.

There are two live broadcast scheduled on July 12, at 11am EDT (4pm BST/UK) and 2pm EDT. To register and learn more about this complimentary event, visit: First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2016/6/20/11G103546/Images/Logo_200-1001491813672.jpg

Contact Information